Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney cancer drug study halted after just 6 patients

NCT ID NCT03846128

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treatment. However, the study was terminated early after enrolling only 6 participants, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sunitinib
What this could lead to
If successful, this could help doctors personalize sunitinib dosing to reduce severe side effects while maintaining effectiveness.
What could go wrong
The study was terminated early with only 6 participants, so results are very limited and may not apply broadly. No new treatment was tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

6 people

The number who actually took part.

Started

Jun 2019

Finished

Oct 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient at least 18 years old * Patient who read and understood the newsletter and signed the consent form * Renal cell carcinoma histologically proven stage IV * Metastatic stage proven on CT, synchronous or metachronous examination * Patient operated on or not from the primary tumor * Eligible for first-line systemic therapy with Sunitinib-targeted therapy for oncology urology * Affiliation to a social security scheme * Effective contraception (as defined by the WHO) for at least 3 months at the inclusion visit, during treatment and for 1 month after the end of the research (negative pregnancy test) * Postmenopausal woman: confirmatory diagnosis (amenorrhea not clinically induced for more than 12 months at inclusion visit) * General condition WHO 0 to 2 * Life expectancy estimated at more than 6 months at baseline Exclusion Criteria: * Non-metastatic disease * Other cancer proven histologically, or in complete remission for less than 2 years * Contraindication to SUTENT 50 mg hard capsules: Hypersensitivity to the active substance or to any of the excipients * History of immunotherapy treatment for kidney cancer, previous treatment with targeted therapies for the same or previous cancer * Pregnant or lactating woman or wishing to breastfeed within 6 months after the last treatment or no known contraception, * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-guardianship or curatorship * Patient currently involved in an interventional trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic kidney cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic kidney cancer

Contacts and locations

Locations

  • CHU de ROUEN

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.